6 months vs 12 Herceptin Her-2 positive patients

Options
cp418
cp418 Member Posts: 7,079
edited June 2014 in Clinical Trials, Research News, Podcasts, and Study Results

http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70225-0/abstract

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

· Share on FacebookShare on Twitter

Comments

  • jenrio
    jenrio Member Posts: 558
    edited June 2013

    Quote: "After 3·5 years follow-up, we failed to show that 6 months of treatment with trastuzumab was non-inferior to 12 months of trastuzumab. Despite the higher rates of cardiac events, 12 months of adjuvant trastuzmab should remain the standard of care."

    Lovely study, we are no closer to the cure at the end of this trial than before.   thanks for the link.

    · Share on FacebookShare on Twitter

Categories